These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 35322374)
1. Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV-DNA level < 2000 IU/mL. Lee H; Jang S; Ahn SH; Kim BK Hepatol Int; 2022 Apr; 16(2):294-305. PubMed ID: 35322374 [TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness Analysis of Antiviral Therapy for Untreated Minimally Active Chronic Hepatitis B to Prevent Liver Disease Progression. Lee H; Kim BK; Jang S; Ahn SH Clin Transl Gastroenterol; 2021 Feb; 12(2):e00299. PubMed ID: 33600103 [TBL] [Abstract][Full Text] [Related]
3. Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis. Huang DQ; Tamaki N; Lee HW; Park SY; Lee YR; Lee HW; Lim SG; Lim TS; Kurosaki M; Marusawa H; Mashiba T; Kondo M; Uchida Y; Kobashi H; Furuta K; Izumi N; Kim BK; Sinn DH Hepatology; 2023 May; 77(5):1746-1756. PubMed ID: 36633913 [TBL] [Abstract][Full Text] [Related]
4. Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL. Lee HW; Park SY; Lee YR; Lee H; Lee JS; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK Am J Gastroenterol; 2022 Feb; 117(2):288-294. PubMed ID: 34506308 [TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load. Sinn DH; Lee J; Goo J; Kim K; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Yoo BC; Paik SW Hepatology; 2015 Sep; 62(3):694-701. PubMed ID: 25963803 [TBL] [Abstract][Full Text] [Related]
6. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Kim JH; Sinn DH; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW Hepatology; 2017 Aug; 66(2):335-343. PubMed ID: 28012257 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of antiviral treatment after resection in hepatitis B virus-related hepatocellular carcinoma patients with compensated cirrhosis. Xie L; Yin J; Xia R; Zhuang G Hepatology; 2018 Oct; 68(4):1476-1486. PubMed ID: 29633304 [TBL] [Abstract][Full Text] [Related]
8. Risk Factors and Nomogram Model for Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients with Low-Level Viremia. Chen YC; Yang CC; Kuo HT; Sheu MJ; Feng IC; Liu CF; Sun CS; Wang SH; Lin CY; Chen CH; Lin SH Int J Med Sci; 2024; 21(9):1661-1671. PubMed ID: 39006848 [No Abstract] [Full Text] [Related]
9. Hepatitis B virus DNA levels and overall survival in hepatitis B-related hepatocellular carcinoma patients with low-level viremia. Kim TS; Sinn DH; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW J Gastroenterol Hepatol; 2019 Nov; 34(11):2028-2035. PubMed ID: 31157456 [TBL] [Abstract][Full Text] [Related]
10. Low Level of Hepatitis B Viremia Compared With Undetectable Viremia Increases the Risk of Hepatocellular Carcinoma in Patients With Untreated Compensated Cirrhosis. Yang J; Choi WM; Shim JH; Lee D; Kim KM; Lim YS; Lee HC; Choi J Am J Gastroenterol; 2023 Jun; 118(6):1010-1018. PubMed ID: 36622283 [TBL] [Abstract][Full Text] [Related]
11. Post-operative recurrence of liver cancer according to antiviral therapy for detectable hepatitis B viremia: A nationwide study. Yun B; Ahn SH; Oh J; Yoon JH; Kim BK Eur J Intern Med; 2023 Jan; 107():66-72. PubMed ID: 36347739 [TBL] [Abstract][Full Text] [Related]
12. The clinical effect of antiviral therapy in patients with hepatitis B virus-related decompensated cirrhosis and undetectable DNA. Lee HA; Lee YS; Jung YK; Kim JH; Yim HJ; Yeon JE; Seo YS; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Kim SU J Gastroenterol Hepatol; 2023 May; 38(5):716-723. PubMed ID: 36681856 [TBL] [Abstract][Full Text] [Related]
13. Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status. Kim MN; Hwang SG; Kim BK; Park JY; Kim DY; Han KH; Kim SU; Ahn SH Gut Liver; 2019 Mar; 13(2):197-205. PubMed ID: 30602075 [TBL] [Abstract][Full Text] [Related]
14. Association of Preoperative Antiviral Treatment With Incidences of Microvascular Invasion and Early Tumor Recurrence in Hepatitis B Virus-Related Hepatocellular Carcinoma. Li Z; Lei Z; Xia Y; Li J; Wang K; Zhang H; Wan X; Yang T; Zhou W; Wu M; Pawlik TM; Lau WY; Shen F JAMA Surg; 2018 Oct; 153(10):e182721. PubMed ID: 30073257 [TBL] [Abstract][Full Text] [Related]
15. Silymarin Synergizes with Antiviral Therapy in Hepatitis B Virus-Related Liver Cirrhosis: A Propensity Score Matching Multi-Institutional Study. Huang CH; Wu VC; Wang CL; Wu CL; Huang YT; Chang SH Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542062 [TBL] [Abstract][Full Text] [Related]
16. Clinical Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma Patients with Undetectable Serum HBV DNA Levels. Chang JI; Sinn DH; Cho H; Kim S; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW Dig Dis Sci; 2022 Sep; 67(9):4565-4573. PubMed ID: 34800218 [TBL] [Abstract][Full Text] [Related]
17. Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients. Kim DS; Park SY; Kim BK; Park JY; Kim DY; Han KH; Lee YR; Tak WY; Kweon YO; Jung I; Han M; Kim EH; Ahn SH; Kim SU J Korean Med Sci; 2021 Apr; 36(16):e105. PubMed ID: 33904261 [TBL] [Abstract][Full Text] [Related]
18. Long-term health and economic benefits of switching to tenofovir alafenamide versus continuing on entecavir in chronic hepatitis B patients with low-level viremia in Saudi Arabia. Sanai FM; Aljawad M; Alghamdi AS; Yehoshua A; Khathlan A; Alghamdi M; Kozma S; Smith N; El-Moustaid F; Jeyakumar S; Kachru N Saudi J Gastroenterol; 2024 Jan; 30(1):23-29. PubMed ID: 37417192 [TBL] [Abstract][Full Text] [Related]
19. Hepatocellular Carcinoma Risk of Compensated Cirrhosis Patients with Elevated HBV DNA Levels according to Serum Aminotransferase Levels. Lee J; Sinn DH; Kim JH; Gwak GY; Kim HS; Jung SH; Paik YH; Choi MS; Lee JH; Koh KC; Yoo BC; Paik SW J Korean Med Sci; 2015 Nov; 30(11):1618-24. PubMed ID: 26539006 [TBL] [Abstract][Full Text] [Related]
20. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis. Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]